Redeye welcomes the regulatory approval of the indication of leg ulcers for ChloraSolv, adding significant market potential for the company. The approval is an important event for the case and further strengthens our thesis, though not impacting our Base Case as such – we had already included it in our forecasts and valuation, which at current levels suggests an attractive upside.